Core Viewpoint - Recently, Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiaries have received approval from the National Medical Products Administration for clinical trials of several injection drugs, indicating progress in their oncology drug development pipeline [1]. Group 1: Clinical Trial Approvals - Hengrui Medicine's subsidiaries, including Suzhou Sediya Biopharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have received clinical trial approval notices for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1]. - The approved drugs will undergo clinical trials, with SHR-7787 injection being tested in a multicenter, open-label Phase II study in patients with malignant solid tumors [1]. Group 2: Regulatory Compliance - The approved drugs were reviewed and found to meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China, allowing for the commencement of clinical trials [1]. - The approval date for the drugs was noted as July 17, 2025, indicating a timeline for the regulatory process [1].